Paradigm Biocapital Advisors LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001855655
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 29 positions · Total reported value $2.07B · Top-10 concentration 68.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 54.3% · 7 new · 6 cut · 6 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2023 13F filing, Paradigm Biocapital Advisors LP disclosed 29 equity positions with a combined reported value of $2.07B. The filing implies a focused portfolio: its ten largest positions account for 68.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were NUVL ($283.91M), ACLX ($203.05M), ARGX ($160.76M). By sector, the heaviest allocations are Health Care 59.9%, Other 40.1%. Versus the prior quarter, allocation shifted toward Other (+10.5pp) and away from Health Care (-10.5pp).
Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 6 and fully exited 6, a turnover rate of 54.3% of positions. The portfolio's overlap with the prior quarter was 64% of names.
The largest new positions opened in Q4 2023 were ASND ($44.30M), ARVN ($38.33M), TARS ($20.76M).
Of the 6 positions fully exited versus the prior quarter, the largest were UTHR ($69.41M), INCY ($52.71M), SNDX ($34.70M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- ASND ASCENDIS PHARMA A/S · $44.30M
- ARVN ARVINAS INC · $38.33M
- TARS TARSUS PHARMACEUTICALS INC · $20.76M
- CRGX CARGO THERAPEUTICS INC · $7.72M
- ZNTL ZENTALIS PHARMACEUTICALS INC · $6.06M
- AVTE AEROVATE THERAPEUTICS INC · $3.24M
Fully Exited (vs previous quarter)
- UTHR UNITED THERAPEUTICS CORP DEL · prev qtr: $69.41M
- INCY INCYTE CORP · prev qtr: $52.71M
- SNDX SYNDAX PHARMACEUTICALS INC · prev qtr: $34.70M
- VRNA VERONA PHARMA PLC · prev qtr: $15.10M
- ROIV ROIVANT SCIENCES LTD · prev qtr: $12.64M
- ETNB 89BIO INC · prev qtr: $5.08M
- COGT COGENT BIOSCIENCES INC · prev qtr: $2.20M
Insider Transactions (Form 4)
Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 28 positions worth $5.34B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-120338 (status: Approved), registered 2021-02-23
- Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 28 positions · $5.34B reported value (Q2 2026)
- Top 10 holdings = 75.2% of reported value
- Largest position: RVMD (REVOLUTION MEDICINES INC) at 22.3%
- Average position size: $190.73M
Sector Tilt
- Health Care 81.2%
- Industrials 0.8%
- (classified holdings cover 82% of value)
Quarterly Activity
- Q2 2026: 7 new, 12 added, 7 reduced, 14 exited
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.86M | $283.91M | 13.69% | Add | |
| 2 |
|
3.66M | $203.05M | 9.79% | Add | |
| 3 |
|
422.58K | $160.76M | 7.75% | Add | |
| 4 |
|
2.39M | $137.81M | 6.64% | Add | |
| 5 |
|
1.89M | $114.00M | 5.50% | Reduce | |
| 6 |
|
7.90M | $110.89M | 5.35% | Add | |
| 7 |
|
4.79M | $104.42M | 5.04% | Add | |
| 8 |
|
1.45M | $99.33M | 4.79% | Add | |
| 9 |
|
2.33M | $98.81M | 4.76% | Reduce | |
| 10 |
|
2.13M | $97.99M | 4.72% | Add | |
| 11 |
|
1.54M | $90.66M | 4.37% | Reduce | |
| 12 |
|
2.31M | $82.29M | 3.97% | Add | |
| 13 |
|
12.61M | $81.22M | 3.92% | Reduce | |
| 14 |
|
3.71M | $67.02M | 3.23% | Add | |
| 15 |
|
3.18M | $60.55M | 2.92% | Add | |
| 16 |
|
351.70K | $44.30M | 2.14% | New | |
| 17 |
|
931.30K | $38.33M | 1.85% | New | |
| 18 |
|
2.17M | $37.09M | 1.79% | Reduce | |
| 19 |
|
1.09M | $29.84M | 1.44% | Reduce | |
| 20 |
|
2.14M | $22.50M | 1.08% | Add | |
| 21 |
|
1.02M | $20.76M | 1.00% | New | |
| 22 |
|
2.27M | $19.83M | 0.96% | Add | |
| 23 |
|
1.26M | $18.16M | 0.88% | Add | |
| 24 |
|
2.92M | $16.75M | 0.81% | Reduce | |
| 25 |
|
6.46M | $14.53M | 0.70% | Hold | |
| 26 |
|
333.33K | $7.72M | 0.37% | New | |
| 27 |
|
400.00K | $6.06M | 0.29% | New | |
| 28 |
|
143.24K | $3.24M | 0.16% | New | |
| 29 |
|
150.00K | $2.14M | 0.10% | Reduce | |
FAQ
What did Paradigm Biocapital Advisors LP buy in 2023-Q4?
In its 2023-Q4 13F filing, Paradigm Biocapital Advisors LP reported 29 equity positions worth $2.07B in aggregate; its largest disclosed positions were NUVL ($283.91M), ACLX ($203.05M), ARGX ($160.76M).
How large is Paradigm Biocapital Advisors LP's portfolio?
Paradigm Biocapital Advisors LP reported $2.07B of long equity holdings across 29 positions as of 2023-Q4. Top-10 holdings account for 68.0% of reported value.
What is Paradigm Biocapital Advisors LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.